Shares of the anti-cancer cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having an unusually strong showing today. Ahead of the opening bell, Adaptimmune released both its third-quarter earnings and a clinical program update for its MAGE-A4 franchise. In an exploratory study of patients with various solid tumors, the company's modified T-cell therapy, known as ADP-A2M4CD8, reportedly produced an overall response rate of 43% in patients with advanced ovarian cancer.